{"id":3679,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/amikacin-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"amikacin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/amikacin-txt\/","title":{"rendered":"Amikacin.txt"},"content":{"rendered":"

Amikacin<\/h1>\n

CLINICAL USE <\/H3>
\nAntibacterial agent
\n

DOSE IN NORMAL RENAL FUNCTION <\/H3>
\n15 mg\/kg\/day in 2 divided doses (maximum
\ndose: 1.5 g\/day; maximum cumulative dose:
\n15 g)
\n

PHARMACOKINETICS <\/H3>
\n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n585.6\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n<20\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n94\u201398\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \n0.22\u20130.29\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n2\u20133\/17\u2013150
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : 5\u20136 mg\/kg every 12 hours
    \n
  • 10 to 20 &nbsp &nbsp : 3\u20134 mg\/kg every 24 hours
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n2 mg\/kg every 24\u201348 hours
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nDialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/
    \nmin<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDialysed. Give 5 mg\/kg after
    \ndialysis.
    \n
  • HDF\/high flux &nbsp :
    \nDialysed. Give 5 mg\/kg after
    \ndialysis.
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nDialysed. 7.5 mg\/kg every
    \n24 hours and monitor levels1
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Botulinum toxin: neuromuscular block\n

    enhanced \u2013 risk of toxicity<\/p>\n

  • Ciclosporin: increased risk of\n

    nephrotoxicity<\/p>\n

  • Cytotoxics: increased risk with platinum\n

    compounds of nephrotoxicity and possibly
    \nof ototoxicity<\/p>\n

  • Diuretics: increased risk of ototoxicity\n

    with loop diuretics<\/p>\n

  • Muscle relaxants: enhanced effects of\n

    non-depolarising muscle relaxants and
    \nsuxamethonium<\/p>\n

  • Parasympathomimetics: antagonism of\n

    effect of neostigmine and pyridostigmine<\/p>\n

  • Tacrolimus: increased risk of\n

    nephrotoxicity
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4><\/p>\n

    Route <\/H4>
    \nIM\/IV<\/p>\n

    Rate of Administration <\/H4>
    \nIV bolus \u2013 slow over 2\u20133 minutes<\/p>\n

    Infusion \u2013 at concentration 2.5 mg\/mL <\/p>\n

    over 30 minutes
    \n(Diluents: sodium chloride 0.9%, glucose <\/p>\n

    5% and others)
    \n

    Comments<\/H4><\/p>\n
  • May be used intraperitoneally\n
  • Can be given in 50 mL. (UK Critical Care\n

    Group, Minimum Infusion Volumes for
    \nfluid restricted critically ill patients, 3rd
    \nEdition, 2006.)<\/p>\n

  • Do not mix physically with any other\n

    antibacterial agents
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Nephrotoxic and ototoxic; toxicity no\n

    worse when hyperbilirubinaemic
    \nSerum levels must be measured for <\/p>\n

    efficacy and toxicity<\/p>\n

  • Peritoneal absorption increases in the\n

    presence of inflammation<\/p>\n

  • Volume of distribution increases with\n

    oedema, obesity and ascites<\/p>\n

  • Peak serum concentration should not\n

    exceed 30 mg\/L<\/p>\n

  • Trough serum concentration should be\n

    less than 5 mg\/L<\/p>\n

  • Amikacin affects auditory function to a\n

    greater extent than gentamicin<\/p>\n","protected":false},"excerpt":{"rendered":"

    Amikacin CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3679","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3679"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3679\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}